ALEXANDRIA, Va.—CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO), announced today that CureMD’s Electronic Health Record (EHR) system is the third to be certified by CancerLinQ® after meeting criteria for interoperability and data standardization. This collaboration will streamline access to CancerLinQ® and drive interoperability among EHR systems.
“We are grateful to work with a company that is committed to removing barriers to sharing electronic health information,” said CancerLinQ LLC Chief Executive Officer Cory Wiegert. “The certification will streamline the flow of data from CureMD to CancerLinQ and facilitate the display of CancerLinQ content in the oncology workflow, giving more practices the opportunity to show leadership in care within their community.”
CureMD is a provider of innovative health information systems and services that transform the administrative and clinical operations of healthcare organizations of all sizes. The CureMD All-in-One Oncology EHR platform is built on a cloud-based solution.
“This certification will further allow our oncology practices to make even more informed treatment decisions based on this real time data,” said Bilal Hashmat, CEO, CureMD. “This will positively influence oncology patient care allowing participating practices to access CancerLinQ’s patient analytics. CureMD’s EHR platform alignment with CancerLinQ’s insights into patient data has the potential to deliver important clinical trends and support evidence-based care.”
CancerLinQ® is a health information technology platform working to improve the quality of cancer care for patients by aggregating and analyzing real-world cancer data. The CancerLinQ® Certified EHR program recognizes systems that meet specific requirements for interoperability and cancer data standardization. To become a CancerLinQ® Certified EHR and maintain this status, an EHR system must do the following, in addition to fulfilling other requirements:
- Support the creation and maintenance of health records including, but not limited to, individually identifiable oncology and/or hematology patient information;
- Maintain a leading industry standard for the recording of precise, structured, and standardized clinical data;
- Meet certain federal standards for EHR technology, interoperability, privacy, and safety;
- Work to achieve the continuous, secure transfer of data to the CancerLinQ® system from patients associated with practices that both participate in CancerLinQ and use the EHR; and
- Participate in efforts among stakeholders in the cancer community to drive improvement of interoperability, establish core data elements, and support efforts to standardize and harmonize data approaches.
For more information on how to participate or apply for EHR certification, please visit CancerLinQ.org.
CancerLinQ® is supported in part through Conquer Cancer®, The ASCO foundation, whose generous donors have helped make the system possible. Major supporters include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Treatment Centers of America®; Chan Soon-Shiong Family Foundation; Genentech BioOncology™; HELSINN; Janssen Oncology; Lilly; Raj Mantena, RPh; Novartis Oncology; Pfizer Oncology; Thomas G. Roberts, Jr., MD and Susan M. DaSilva; and Susan G. Komen®.
CancerLinQ® and CancerLinQ Discovery® are projects of CancerLinQ LLC.
Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.